Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World November 8, 2006 Victoria Gill	Molecular Signals of Schizophrenia Identified Researchers have identified specific biomarkers for schizophrenia, a discovery which could pave the way to more accurate diagnostics, improved treatments, and could even be the starting point for the development of preventative medicines.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
Chemistry World November 16, 2011 Helen Potter	Early diagnosis for Alzheimer's and Parkinson's US scientists have developed a biosensor that could detect the early stages of Alzheimer's disease and Parkinson's disease by measuring low concentrations of protein aggregates in cerebrospinal fluid.
Chemistry World March 28, 2014 Michael Parkin	Rare-cell analysis platform pursues neurodegeneration answers A technique for spotting the small numbers of immune cells that cross the blood -- brain barrier into the cerebral spinal fluid may offer early clues on neurodegenerative disease progression.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
Chemistry World October 14, 2009 Phil Taylor	Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease.
BusinessWeek July 15, 2010 Lopatto & Matsuyama	The Race for Diagnostic Tests for Alzheimer's GE, Bayer, and Avid are vying to be first to market an early test for Alzheimer's.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
Chemistry World July 20, 2012 Michael Parkin	New supramolecular Alzheimer's drugs Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer's disease, say scientists in China.
Chemistry World August 25, 2011 David Barden	Rapid Route to Huperzine A US chemists have devised an efficient synthesis of a natural product with great potential as a protectant against chemical warfare agents and in the treatment of Alzheimer's disease.
Chemistry World February 7, 2011 Carl Saxton	Targeting memory loss A new treatment for Alzheimer's disease has been developed by Canadian and US scientists.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool October 10, 2011 Frank Vinluan	TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment.
The Motley Fool April 11, 2011 Brian Orelli	Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected.
Chemistry World July 30, 2008 Sarah Houlton	A metal trap to stop Alzheimer's Trapping metals could prove a key to curing Alzheimer's disease, according to the promising results of early clinical trials on a compound called PBT2.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
HHMI Bulletin May 2011 Sarah C.P. Williams	Nourishing Neural Stem Cells with CSF Inside your skull, your brain is floating in a clear liquid. This liquor cerebrospinalis, or cerebrospinal fluid, until recently was considered simply cushioning for the brain.
Chemistry World May 21, 2013 Emma Stoye	B-vitamins may delay Alzheimer's onset UK researchers have found that high doses of B-vitamins -- including folic acid, vitamin B12 and vitamin B6 -- can slow down brain tissue atrophy, a wasting process associated with Alzheimer's disease.
Chemistry World July 22, 2009 Phil Taylor	New drug turns Alzheimer's theory on its head Researchers have been left puzzled by data showing that the antihistamine dimebolin, a drug with promising activity in improving Alzheimer's symptoms, actually seems to increase levels of the toxic protein beta amyloid.
AskMen.com Jacob Franek	Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information.
Chemistry World November 20, 2013 Rebecca Brodie	Therapeutic screening for Alzheimer's disease Scientists in Canada and the US hope a system they have developed for monitoring amyloid- aggregation on a chip could be used to find new treatments for Alzheimer's disease.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
Chemistry World June 2011	Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
Chemistry World June 27, 2012 Helen Bache	Schizophrenia: a disease of the brain? Scientists in China have unearthed further evidence that a malfunction of the immune system contributes to the development of schizophrenia.
The Motley Fool March 3, 2010 Brian Orelli	A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.
Nurse Practitioner August 2011 Davis et al.	Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups.
The Motley Fool January 19, 2011 Brian Orelli	High Stakes at Tomorrow's FDA Panel Meeting It's more than just Eli Lilly on the line.
Chemistry World December 21, 2006 Tom Westgate	Molecular Probe Identifies Patients at Risk of Alzheimer's A new molecule could provide an early warning system for Alzheimer's disease, US researchers hope.
American Family Physician September 15, 2004 Verrees & Selman	Management of Normal Pressure Hydrocephalus Normal pressure hydrocephalus (NPH) is often is treatable, and accurate recognition of the clinical triad coupled with radiographic evidence most commonly identifies likely responders, though no definitive method exists to prove diagnosis.
Chemistry World November 2, 2006 Michael Gross	Alzheimer's Century Researchers worldwide are commemorating the centenary of Alois Alzheimer's first description of the dementia named after him.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Registered Rep. August 30, 2011 Amy Burroughs	When Your Client Has Alzheimer's One early sign of the disease is trouble managing money, which puts financial advisors on the front lines.
Chemistry World June 14, 2009 Hayley Birch	New technique probes Alzheimer's aggregates US and UK researchers have used a new technique to identify what they think could be the primary toxic species in the development of Alzheimer's disease
The Motley Fool July 29, 2009 Brian Orelli	Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
The Motley Fool March 18, 2011 Brian Orelli	Forget Getting Approved, for Now The FDA wants more information on Eli Lilly's Amyvid.
Chemistry World December 9, 2013 James Urquhart	Drug fix for misfolded proteins promises hope for incurable diseases Researchers have been looking into pharmacological chaperones or pharmacoperones. They might treat diseases brought about by genetic mutations that cause otherwise functional proteins to become misfolded or misrouted.
Reactive Reports May 2007 David Bradley	Meeting of Molecular Movie Stars New footage confirms Linus Pauling's theory of chemical bonding proposed half a century ago, and could help explain molecular recognition processes important throughout supramolecular chemistry and molecular biology.
Chemistry World August 24, 2006 Jessica Ebert	Alzheimer's Researchers Tackle Waste Disposal The memory of mice with Alzheimer's-like symptoms is improved by inoculating the mice with an enzyme involved in protein degradation, report US researchers. The work could lead to new therapies for patients with Alzheimer's disease.
Chemistry World June 14, 2011	A New Spin on Protein NMR A new technique will allow researchers to study protein structure in greater detail using NMR.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Financial Planning August 1, 2009 Donna Mitchell	Alzheimer's Toll A study surveyed 369 advisors in the U.S. to gauge their understanding of Alzheimer's and their preparedness for dealing with clients who have the disease.